Skip to content
Reckitt Benckiser
Search
Join RB’s networks
Facebook
LinkedIn
Twitter
YouTube
Google Plus
Weibo
RB Early Life Blog
Share
Sitemap
HTML version
Text only version
RB worldwide
Global locations
Executive Committee
The Board
RB history
Vision and values
Contact us
Careers & students
Apply now
Why join us?
Jobs for professionals
Graduates & Interns
What it's like at RB
Brand Me
Just for fun
Innovators
Products
People
Awards
Our brands
Powerbrands on the shelf
Products around the home
Commercial break
Search RB Brands A-Z
Category performance
Healthcare Brands Employee Reporting
Suboxone, Subutex & Temgesic adverse events reporting
Our responsibility
betterbusiness
Our Home Our Planet
Trees for Change
Community
Healthier kids Happier homes
Policies & reports
Contact us
Investors & media
Announcements & presentations
The talk about RB
Investor information
Category performance
Corporate governance
Share price information
Shareholder information
Patient organisation donations
Joint working executive summaries
Newsletter registration
Financial support for Healthcare Professionals
Contact us
Home
>
Investors & media
>
Investor information
>
Online Annual Report 2011
Investors & media
Announcements & presentations
The talk about RB
Investor information
Online Annual Report 2012
Online Annual Report 2011
Strong foundation
Powerbrands
Powermarkets
Progress and expansion
Results and responsibility
Online Annual Report 2010
Category performance
Corporate governance
Share price information
Shareholder information
Patient organisation donations
Joint working executive summaries
Newsletter registration
Financial support for Healthcare Professionals
Contact us
Chief Executive's Statement
2011 was Reckitt Benckiser’s 12
th
consecutive year of high quality growth, and another year in which RB beat its targets.
Total net revenue grew +13%
1
to £9,485m – ahead of the +12% target.
Excellent growth in emerging markets and Powerbrands Dettol, Nurofen, Mucinex, Strepsils, Gaviscon and Harpic.
Like-for-like growth, excluding acquisitions, of +4%
1
.
Recently acquired SSL grew net revenue by +6%
1
to £843m like-for-like.
Suboxone film captured a 48% volume share of the US market.
Adjusted net income grew +11%
1
to £1,818m – ahead of the +10% target.
Strong cash flow took net debt down to £1,795m.
In 2012 we are targeting total Company net revenue growth excluding RB Pharmaceuticals of 200 basis points (bps) above our market growth rate. We expect the market to grow at 1-2%. 2012 will be a year of higher investment, but we still aim to maintain our operating margins
2
.
Rakesh Kapoor
Chief Executive
1
At constant exchange rates
2
Excluding RB Pharmaceuticals
Financial highlights of 2011
* Includes final 2011 dividend of 70p recommended by the Board
Read more
> Chief Executive's Statement
> Strong foundation. Healthy future
To deliver tomorrow we need to reshape today.
> Powerbrands focus
Our future in ‘health, hygiene and home’.
> Powermarkets focus
A new organisation structure will drive strategy.
> Progress and expansion
New medium term performance indicators.
> Results and responsibility
Our commitment beyond the commercial.
Print this page
Downloads
Click to download PDFs
Full Annual Report & Accounts 2011
Annual Report Highlights
Download an individual section
Chairman's Statement
Chief Executive's Statement
Business Review 2011
Board of Directors & Executive Committee
Report of the Directors
Corporate Governance Report
Statement of Directors’ Responsibilities
Directors’ Remuneration Report
Independent Auditor’s Report
The financial statements
Shareholder information
Notice of Meeting
AGM map
See our previous year's Annual Reports